| abstract |
Disclosed herein are fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof wherein substituents are as defined within the specification. Such compounds exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also disclosed are pharmaceutical compositions containing said compounds and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. The use of the compounds of Formula (Ia) in combination with other active agents such as those belonging to the class of รก-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like are further disclosed. |